Drugs and Devices

FDA approves new combination treatment for acute myeloid leukemia

On April 28, the U.S. Food and Drug Administration (FDA) approved Rydapt (midostaurin) for the treatment of adult patients with newly diagnosed acute myeloid leukemia who have the genetic mutation FLT3, in combination with chemotherapy. Read more


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Newsletter Subscribe

  • This field is for validation purposes and should be left unchanged.

Test Your Nursing Knowledge

Answer this interactive quiz to be entered to win a gift card.

  • This field is for validation purposes and should be left unchanged.

Insights Blog

Today’s News in Nursing

Shares